EZZ Life Science Holdings Ltd (ASX:EZZ) chairman Glenn Cross joins Proactive’s Elisha Newell to detail the company’s value proposition. With a focus on genomic research and gene technology, EZZ hopes to address four key human health challenges: genetic longevity, human papillomavirus, helicobacter pylori and weight management. The company has just inked a tripartite agreement with two leading multinational pharmaceutical companies, designed to bring new products and wellness solutions to the market.
EZZ Life Science Holdings brings genomic research to the ASX
